NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

UCLA owns the IP, NWBO licensed it, and as far as I'm aware it has expired (the licensing). Along with the DCVax Prostate IP they licensed. That expired somewhat recently too, as far as I aware.

The bottom there was just a misread by you. Non sequitur (they weren't talking about the Liau study anymore in that highlighted section).

BCG is used to differentiate DC in Direct, but not L. But it's a minor point anyway--the main reasons L is almost certainly useless is due to the impact on DC when mixed with freeze thaw necrosed WTL. This can be curbed a bit when tumor cells are pre stressed but DCVax L has no such step. The DC in DCVax L are thus fixed in a tolerogenic state. And also there is 1:3,000 ratio of self antigens to relevant TAA in the slurry. Needle in a haystack. But even if some tiny % of the DC in DCVax L manage to load properly and are somehow able to reach maturity and are not also not phagocytized at the injection cite (at this point were talking maybe very very few--less than 0.5% I would guess), the "immune response" they may illicit will not thwart progression of disease appreciably enough, and ACTUALLY may theoretically exacerbate what appears to be PD, thus causing a worse PFS curve than control (see AV0113).

I've said all this before. Not sure if people are following what I'm saying or not at this point.

Anyway it's just money guys. Right?